… ProQR Doses First LCA 10 Patient in ClinicalTrial of QR-110, ProQR’s Lead Program for Genetic Blindness … program is the first in a planned series of ophthalmology trials utilizing our RNA therapy platform to target the …
… ProQR Announces Clearance of IND to Start ClinicalTrial of QR-421a in Usher Syndrome Type 2 Patients LEIDEN, … To date, there are no approved treatments or products in clinical development that treat the vision loss associated …
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.
… ProQR Announces Clearance of IND to Start ClinicalTrial of QR-1123 in Patients with Autosomal Dominant … our fifth IND in less than five years and our third clinical program for severe genetic eye diseases. With a …
ProQR to host a conference call to discuss the top-line results of the Phase 2/3 Illuminate clinical trial of investigational RNA therapy sepofarsen in CEP20-mediated LCA10.
